Abstract:Due to their unique properties, dihydroazaindoles are important fragments of active pharmaceutical ingredients and are of great interest in the pharmaceutical industry. In this manuscript, a scalable and economical process for the synthesis of a complex (R)-2-(4-fluorophenyl)-2-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid ( R )-1 on multikilogram scale is described. The synthesis was advanced through a second-generation synthetic strategy that did not rely on chiral Supercritical Fluid Chromatography separation, which was the highest cost driver. Through systematic screening of chemical resolution, we found that compound ( R )-1 can be isolated with high (>99%) enantiomeric excess. Furthermore, the mother liquor from the first resolution process was recyclable to racemize the S-isomer into ( R )-1 and ( S ) - 1 mixtures, which could be used for an additional chemical resolution process. The precious palladium (Pd) complexes could be reduced from 20 mol % to 1 mol %, and the long lead time building blocks were safely prepared in-house. Advanced intermediates were efficiently synthesized by reducing isolation steps through one-pot process development. The regulatory starting material compound ( R )-1·HCl was isolated with a high purity profile after di-p-toluoyl-d-tartaric acid salt breaking and HCl salt formation.

Development of a Scalable Synthesis of Mevidalen (LY3154207), an Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor

Synthesis and Preclinical Characterization of LY3154885, a Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Nonclinical Drug-Drug Interaction Risk Profile.

Development and Production of an Enantioselective Tetrahydroisoquinoline Synthesis Enabled by Continuous Cryogenic Lithium–Halogen Exchange

Early Process Development and Scale-Up of a Positive Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor

Optimization and Development of a Scalable Palladium-Catalyzed C–H Activation Process for the Geometry-Selective Preparation of Kilograms of YLF466D, a Potent AMP-Activated Protein Kinase Activator

Development of A Large Scale Asymmetric Synthesis of the Glucocorticoid Agonist Bi 653048 Bs H3po4

Development of a Scalable Synthesis Toward a KRAS G12C Inhibitor Building Block Bearing an All-Carbon Quaternary Stereocenter, Part 1: from Discovery Route to Kilogram-Scale Production

Large-Scale Synthesis of LPA1-Receptor Antagonist ACT-1016-0707

3-Benzyl-1,3-oxazolidin-2-ones As Mglur2 Positive Allosteric Modulators: Hit-to Lead and Lead Optimization

Discovery of VU6007496: Challenges in the Development of an M1 Positive Allosteric Modulator Backup Candidate

Process Development of a Macrocyclic Peptide Inhibitor of PD-L1

Development of a Concise Multikilogram Synthesis of LPA-1 Antagonist BMS-986020 Via a Tandem Borylation–Suzuki Procedure

Development of a multigram synthetic process to clinical candidate TMP195, a class IIa histone deacetylase selective inhibitor

Process Development and Scale-Up of a Novel Atypical DAT Inhibitor ( S )-CE-123

Development Of A Concise, Scalable Synthesis Of A Ccr1 Antagonist Utilizing A Continuous Flow Curtius Rearrangement

Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks

Toward the Development of a Manufacturing Process for Milvexian: Scale-Up Synthesis of the Side Chain

Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia

A SHORT, EFFICIENT SYNTHESIS OF THE NOVEL CHOLINERGIC CHANNEL ACTIVATOR, ABT-418, FROM L-PROLINE

Building a Quaternary Stereogenic Center on Dihydroazaindole Carboxylic Acid through Scalable Process Development